2, 3, 5, 4′-Tetrahydroxystilbene-2-O-Beta-D-Glucoside Improves Gastrointestinal Motility Disorders in STZ-Induced Diabetic Mice

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Chang, Mu Jun ^a   Xiao, Jun Hua ^a   Wang, Yong ^a   Yan, Yong Li ^a   Yang, Jun ^a   Wang, Jia Ling ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,5,4' TETRAHYDROXYSTILBENE 2 O BETA DEXTRO GLUCOSIDE; ANTIDIABETIC AGENT; ANTIOXIDANT; GLUCOSE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE; NEURONAL NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SIRTUIN 1; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL TRANSIT; GLUCOSE BLOOD LEVEL; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; STOMACH EMPTYING; STOMACH PROTECTION; STREPTOZOCIN DIABETES; UPREGULATION;

ANIMALS; CASPASE 3; DIABETES MELLITUS, EXPERIMENTAL; GASTROINTESTINAL MOTILITY; GLUCOSIDES; GLUTATHIONE PEROXIDASE; MALONDIALDEHYDE; MICE; NITRIC OXIDE SYNTHASE TYPE I; OXIDATIVE STRESS; PHOSPHORYLATION; STILBENES; STREPTOZOCIN;

MUS;

EID: 84870723756     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050291     Document Type: Article

References (55)

1. Verne GN, Sninsky CA (1998) Diabetes and the gastrointestinal tract. Gastroenterol Clin North Am 27: 861-874, vi-vii.
2. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, et al. (2001) Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med 161: 1989-1996.
3. Bhor VM, Raghuram N, Sivakami S, (2004) Oxidative damage and altered antioxidant enzyme activities in the small intestine of streptozotocin-induced diabetic rats. Int J Biochem Cell Biol 36: 89-97.
4. Chandrasekharan B, Anitha M, Blatt R, Shahnavaz N, Kooby D, et al. (2011) Colonic motor dysfunction in human diabetes is associated with enteric neuronal loss and increased oxidative stress. Neurogastroenterol Motil 23: 131-138, e126.
5. Pereira RV, de Miranda-Neto MH, da Silva Souza ID, Zanoni JN, (2008) Vitamin E supplementation in rats with experimental diabetes mellitus: analysis of myosin-V and nNOS immunoreactive myenteric neurons from terminal ileum. J Mol Histol 39: 595-603.
6. Guo C, Quobatari A, Shangguan Y, Hong S, Wiley JW, (2004) Diabetic autonomic neuropathy: evidence for apoptosis in situ in the rat. Neurogastroenterol Motil 16: 335-345.
7. Anitha M, Gondha C, Sutliff R, Parsadanian A, Mwangi S, et al. (2006) GDNF rescues hyperglycemia-induced diabetic enteric neuropathy through activation of the PI3K/Akt pathway. J Clin Invest 116: 344-356.
8. Surendran S, Kondapaka SB, (2005) Altered expression of neuronal nitric oxide synthase in the duodenum longitudinal muscle-myenteric plexus of obesity induced diabetes mouse: implications on enteric neurodegeneration. Biochem Biophys Res Commun 338: 919-922.
9. Furlan MM, de Miranda Neto MH, Sant'ana Dde M, Molinari SL, (1999) Number and size of myenteric neurons of the duodenum of adult rats with acute diabetes. Arq Neuropsiquiatr 57: 740-745.
10. Watkins CC, Sawa A, Jaffrey S, Blackshaw S, Barrow RK, et al. (2000) Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest 106: 373-384.
11. Furlan MM, Molinari SL, Miranda Neto MH, (2002) Morphoquantitative effects of acute diabetes on the myenteric neurons of the proximal colon of adult rats. Arq Neuropsiquiatr 60: 576-581.
12. Korenaga K, Micci MA, Taglialatela G, Pasricha PJ, (2006) Suppression of nNOS expression in rat enteric neurones by the receptor for advanced glycation end-products. Neurogastroenterol Motil 18: 392-400.
13. Vincent AM, Perrone L, Sullivan KA, Backus C, Sastry AM, et al. (2007) Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology 148: 548-558.
14. Jeyabal PV, Kumar R, Gangula PR, Micci MA, Pasricha PJ, (2008) Inhibitors of advanced glycation end-products prevent loss of enteric neuronal nitric oxide synthase in diabetic rats. Neurogastroenterol Motil 20: 253-261.
15. Cellek S, Foxwell NA, Moncada S, (2003) Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes 52: 2353-2362.
16. Voukali E, Shotton HR, Lincoln J, (2011) Selective responses of myenteric neurons to oxidative stress and diabetic stimuli. Neurogastroenterol Motil 23: 964-e411.
17. Chandrasekharan B, Srinivasan S, (2007) Diabetes and the enteric nervous system. Neurogastroenterol Motil 19: 951-960.
18. Bult H, Boeckxstaens GE, Pelckmans PA, Jordaens FH, Van Maercke YM, et al. (1990) Nitric oxide as an inhibitory non-adrenergic non-cholinergic neurotransmitter. Nature 345: 346-347.
19. Martinez-Cuesta MA, Massuda H, Whittle BJ, Moncada S, (1995) Impairment of nitrergic-mediated relaxation of rat isolated duodenum by experimental diabetes. Br J Pharmacol 114: 919-924.
20. Jenkinson KM, Reid JJ, (1995) Effect of diabetes on relaxations to non-adrenergic, non-cholinergic nerve stimulation in longitudinal muscle of the rat gastric fundus. Br J Pharmacol 116: 1551-1556.
21. Choi KM, Gibbons SJ, Nguyen TV, Stoltz GJ, Lurken MS, et al. (2008) Heme oxygenase-1 protects interstitial cells of Cajal from oxidative stress and reverses diabetic gastroparesis. Gastroenterology 135: 2055-2064, 2064 e2051-2052.
22. Kashyap P, Farrugia G, (2011) Oxidative stress: key player in gastrointestinal complications of diabetes. Neurogastroenterol Motil 23: 111-114.
23. Vincent AM, Russell JW, Low P, Feldman EL, (2004) Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 25: 612-628.
24. Curtin JF, Donovan M, Cotter TG, (2002) Regulation and measurement of oxidative stress in apoptosis. J Immunol Methods 265: 49-72.
25. Owuor ED, Kong AN, (2002) Antioxidants and oxidants regulated signal transduction pathways. Biochem Pharmacol 64: 765-770.
26. Srinivasan S, Stevens M, Wiley JW, (2000) Diabetic peripheral neuropathy: evidence for apoptosis and associated mitochondrial dysfunction. Diabetes 49: 1932-1938.
27. Schmeichel AM, Schmelzer JD, Low PA, (2003) Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 52: 165-171.
28. Shotton HR, Broadbent S, Lincoln J, (2004) Prevention and partial reversal of diabetes-induced changes in enteric nerves of the rat ileum by combined treatment with alpha-lipoic acid and evening primrose oil. Auton Neurosci 111: 57-65.
29. Zhang SH, Wang WQ, Wang JL, (2009) Protective effect of tetrahydroxystilbene glucoside on cardiotoxicity induced by doxorubicin in vitro and in vivo. Acta Pharmacol Sin 30: 1479-1487.
30. Wang T, Gu J, Wu PF, Wang F, Xiong Z, et al. (2009) Protection by tetrahydroxystilbene glucoside against cerebral ischemia: involvement of JNK, SIRT1, and NF-kappaB pathways and inhibition of intracellular ROS/RNS generation. Free Radic Biol Med 47: 229-240.
31. Wang X, Zhao L, Han T, Chen S, Wang J, (2008) Protective effects of 2,3,5,4′-tetrahydroxystilbene-2-O-beta-d-glucoside, an active component of Polygonum multiflorum Thunb, on experimental colitis in mice. Eur J Pharmacol 578: 339-348.
32. Zeng C, Xiao JH, Chang MJ, Wang JL, (2011) Beneficial effects of THSG on acetic acid-induced experimental colitis: involvement of upregulation of PPAR-gamma and inhibition of the Nf-Kappab inflammatory pathway. Molecules 16: 8552-8568.
33. Matsuda NM, Miller SM, (2010) Non-adrenergic non-cholinergic inhibition of gastrointestinal smooth muscle and its intracellular mechanism(s). Fundam Clin Pharmacol 24: 261-268.
34. Kobayashi Y, Furukawa-Hibi Y, Chen C, Horio Y, Isobe K, et al. (2005) SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int J Mol Med 16: 237-243.
35. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, et al. (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159.
36. Giannakou ME, Partridge L, (2004) The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol 14: 408-412.
37. Kubota S, Kurihara T, Mochimaru H, Satofuka S, Noda K, et al. (2009) Prevention of ocular inflammation in endotoxin-induced uveitis with resveratrol by inhibiting oxidative damage and nuclear factor-kappaB activation. Invest Ophthalmol Vis Sci 50: 3512-3519.
38. Tang BL, (2006) SIRT1, neuronal cell survival and the insulin/IGF-1 aging paradox. Neurobiol Aging 27: 501-505.
39. Dali-Youcef N, Lagouge M, Froelich S, Koehl C, Schoonjans K, et al. (2007) Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann Med 39: 335-345.
40. Saini A, Al-Shanti N, Sharples A, Stewart C (2011) Sirt1 regulates skeletal myoblast survival and enhances differentiation in the presence of resveratrol. Exp Physiol.
41. Kruszewski M, Szumiel I, (2005) Sirtuins (histone deacetylases III) in the cellular response to DNA damage-facts and hypotheses. DNA Repair (Amst) 4: 1306-1313.
42. Yamamori T, DeRicco J, Naqvi A, Hoffman TA, Mattagajasingh I, et al. (2010) SIRT1 deacetylates APE1 and regulates cellular base excision repair. Nucleic Acids Res 38: 832-845.
43. Chaudhary N, Pfluger PT, (2009) Metabolic benefits from Sirt1 and Sirt1 activators. Curr Opin Clin Nutr Metab Care 12: 431-437.
44. Liang F, Kume S, Koya D, (2009) SIRT1 and insulin resistance. Nat Rev Endocrinol 5: 367-373.
45. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, et al. (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450: 712-716.
46. Guarente L, (2006) Sirtuins as potential targets for metabolic syndrome. Nature 444: 868-874.
47. Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, et al. (2004) Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 53: 1621-1629.
48. Sulaiman M, Matta MJ, Sunderesan NR, Gupta MP, Periasamy M, et al. (2010) Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 298: H833-843.
49. Wang Y, Shi X, Qi J, Li X, Uray K, et al. (2012) SIRT1 inhibits the mouse intestinal motility and epithelial proliferation. Am J Physiol Gastrointest Liver Physiol 302: G207-217.
50. Mersmann J, Tran N, Zacharowski PA, Grotemeyer D, Zacharowski K, (2008) Rosiglitazone is cardioprotective in a murine model of myocardial I/R. Shock 30: 64-68.
51. Lee TI, Kao YH, Chen YC, Chen YJ, (2009) Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors. Eur J Clin Invest 39: 23-30.
52. Chung SS, Kim M, Youn BS, Lee NS, Park JW, et al. (2009) Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor gamma in human skeletal muscle cells. Mol Cell Biol 29: 20-30.
53. Yi JH, Park SW, Brooks N, Lang BT, Vemuganti R, (2008) PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res 1244: 164-172.
54. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, et al. (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429: 771-776.
55. De Winter BY, Bredenoord AJ, De Man JG, Moreels TG, Herman AG, et al. (2002) Effect of inhibition of inducible nitric oxide synthase and guanylyl cyclase on endotoxin-induced delay in gastric emptying and intestinal transit in mice. Shock 18: 125-131.